How has the narcolepsy market evolved, and where is it heading next?
The narcolepsy market size has grown rapidly in recent years. It will grow from $3.56 billion in 2024 to $3.99 billion in 2025 at a compound annual growth rate (CAGR) of 12.0%. The growth in the historic period can be attributed to increased awareness of narcolepsy, the development, and improvement of diagnostic tools, the introduction of new pharmacological treatments, research and development investments, and enhanced patient education initiatives.
The narcolepsy market size is expected to see rapid growth in the next few years. It will grow to $6.21 billion in 2029 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to the rising prevalence of sleep disorders, improved healthcare infrastructure, supportive government policies, an increasing geriatric population, and rising consumer health awareness. Major trends in the forecast period include advancements in genetic research, technological innovations in diagnostics, the introduction of novel drugs and treatment modalities, strategic collaborations and partnerships between key market players, and digital health tools and telemedicine.
Get Your Free Sample of The Global Narcolepsy Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16491&type=smp
What have been the primary factors driving the narcolepsy market’s growth?
The growing number of obese people is expected to propel the growth of the narcolepsy market going forward. Obesity is a medical condition characterized by an excessive accumulation of body fat, which poses a health risk. The number of obese people is rising due to increasingly sedentary lifestyles, poor dietary habits, and environmental factors that promote calorie-dense food consumption and reduce physical activity. Obesity can contribute to narcolepsy by disrupting metabolic and hormonal balances, potentially leading to changes in sleep patterns and the regulation of wakefulness. For instance, in March 2022, according to the World Health Organization, a Switzerland-based specialized United Nations agency responsible for worldwide public health, around 1 billion individuals, comprising 650 million adults, 340 million teenagers, and 39 million children, were classified as obese, with this figure continuing to rise. Projections indicate that by 2025, approximately 167 million adults and children will suffer health consequences due to excess weight. Therefore, the growing number of obese people is driving the growth of the narcolepsy market.
What are the key segments within the narcolepsy market?
The narcolepsy market covered in this report is segmented –
1) By Type: Type 1, Type 2
2) By Treatment: Antidepressants, Stimulants, Sodium Oxybate, Other Treatments
3) By Diagnosis: Polysomnogram, Multiple Sleep Latency Test
4) By End Users: Hospitals, Retail Pharmacies, Other End Users
Subsegments:
1) By Type 1: Stimulant Medications, Antidepressants, Sodium Oxybate, Immunosuppressive Treatments
2) By Type 2: Stimulant Medications, Sodium Oxybate, Antidepressants
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/narcolepsy-global-market-report
Which key players are shaping the narcolepsy market?
Major companies operating in the narcolepsy market are Pfizer Inc., Merck & Co. Inc, Novartis AG, Takeda Pharmaceutical Company Limited, Viatris Inc, Teva Pharmaceutical Industries, Otsuka Pharmaceutical, Sumitomo Pharma Company Limited, Jazz Pharmaceuticals, Ono Pharmaceutical Co. Ltd, Lupin Pharmaceuticals, Alkermes, Harmony Biosciences, Arena Pharmaceuticals, Cerevel Therapeutics, Axsome Therapeutics Inc., Avadel Pharmaceuticals, NLS Pharmaceutics AG, KemPharm, Suven Life Sciences Ltd
How will emerging trends drive the narcolepsy market throughout the forecast period?
Major companies operating in the narcolepsy market are increasing their focus on developing novel medications, such as extended-release sodium oxybate, to address the growing demand for effective treatments. Extended-release sodium oxybate is a medication used in the treatment of narcolepsy. The extended-release formulation allows for controlled release of the medication over a longer period, providing sustained symptom relief throughout the night and improving sleep quality for individuals with narcolepsy. For instance, in June 2023, Avadel Pharmaceuticals plc, an Ireland-based pharmaceutical company, launched LUMRYZ in the United States. LUMRYZ is an extended-release formulation of sodium oxybate approved by the FDA for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. It is the first and only once-at-bedtime oxybate treatment for narcolepsy, offering a significant improvement over twice-nightly oxybate products by avoiding the need to wake up for a second dose at night.
How do regional factors impact the narcolepsy market, and which region is the largest contributor?
North America was the largest region in the narcolepsy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the narcolepsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Narcolepsy Market Report 2025 Offer?
The narcolepsy market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Narcolepsy is a chronic neurological disorder that affects the brain’s ability to regulate sleep-wake cycles. People with narcolepsy often experience excessive daytime sleepiness and uncontrollable episodes of falling asleep during the day, which can occur during any type of activity. Narcolepsy is frequently accompanied by cataplexy, a sudden loss of muscle tone triggered by strong emotions.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16491
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
